Danaher Corporation (DHR)

Currency in USD
215.75
-3.78(-1.72%)
Closed·
217.17+1.42(+0.66%)
·
DHR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
214.94220.00
52 wk Range
171.00242.80
Key Statistics
Prev. Close
215.75
Open
219.08
Day's Range
214.94-220
52 wk Range
171-242.8
Volume
4.14M
Average Volume (3m)
3.6M
1-Year Change
2.7332%
Book Value / Share
74.37
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DHR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
264.86
Upside
+22.76%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 8 consecutive years

Danaher Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Danaher Corporation Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians’ offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.

Danaher Corporation SWOT Analysis


Life Sciences Leade
Danaher Corporation, a $150B market cap giant, dominates life sciences, diagnostics, and CROs sectors with robust financial health and strategic market positioning
Financial Trajectory
Analysts project steady growth for Danaher, with revenue expected to reach $27.67B by 2027 and EPS rising to $9.56, showcasing strong financial outlook
Strategic Evolution
Explore Danaher's proactive cost-saving measures and operational efficiencies, aimed at expanding margins into the mid-30s and enhancing shareholder value
Market Dynamics
Average analyst price target of $284, reflecting varied perspectives on Danaher's growth potential amid biotech recovery and ongoing challenges in China
Read full SWOT analysis

Danaher Corporation Earnings Call Summary for Q4/2025

  • Danaher exceeded Q4 2025 forecasts with EPS of $2.23 vs $2.14 expected and revenue of $6.84B vs $6.79B, though shares fell 6.84% in pre-market trading
  • Full-year revenue reached $24.6B with 2% core revenue growth, 28.2% adjusted operating margin, and strong free cash flow of $5.3B (145% conversion ratio)
  • CEO Rainer Blair expressed optimism about Danaher's positioning in bioprocessing and life sciences, stating 'our businesses are in excellent end markets'
  • For 2026, the company projects 3%-6% core revenue growth with adjusted EPS of $8.35-$8.50, and expects low single-digit growth in Q1 2026
  • The bioprocessing sector is forecasted to grow at high single digits, while diagnostics should see low single-digit growth in the coming year
Last Updated: 2026-02-03, 05:04 a/m
Read Full Transcript

Compare DHR to Peers and Sector

Metrics to compare
DHR
Peers
Sector
Relationship
P/E Ratio
42.4x39.4x−0.5x
PEG Ratio
−9.320.780.00
Price/Book
2.9x3.9x2.6x
Price / LTM Sales
6.2x5.5x3.3x
Upside (Analyst Target)
25.1%0.0%48.1%
Fair Value Upside
Unlock2.2%7.7%Unlock

Analyst Ratings

22 Buy
3 Hold
0 Sell
Ratings:
25 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 264.86
(+22.76% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy270.00+25.14%-MaintainJan 29, 2026
KeyBanc
Buy310.00+43.68%-MaintainJan 29, 2026
Baird
Buy251.00+16.34%247.00MaintainJan 29, 2026
Deutsche Bank
Buy270.00+25.14%250.00MaintainJan 29, 2026
Jefferies
Buy265.00+22.83%255.00MaintainJan 28, 2026

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.03%
Dividend Yield
0.59%
Industry Median 1.36%
Annualized payout
1.28
Paid quarterly
5-Years Growth
+12.20%
Growth Streak

Earnings

Latest Release
Jan 28, 2026
EPS / Forecast
2.23 / 2.14
Revenue / Forecast
6.84B / 6.79B
EPS Revisions
Last 90 days

DHR Income Statement

People Also Watch

362.42
SYK
+0.49%
434.91
INTU
-2.41%
30.85
CMCSA
+1.15%
102.00
SCHW
-1.81%

FAQ

What Is the Danaher (DHR) Stock Price Today?

The Danaher stock price today is 215.75

What Stock Exchange Does Danaher Trade On?

Danaher is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Danaher?

The stock symbol for Danaher is "DHR."

Does Danaher Pay Dividends? What’s The Current Dividend Yield?

The Danaher dividend yield is 0.59%.

What Is the Danaher Market Cap?

As of today, Danaher market cap is 152.51B.

What Is Danaher's Earnings Per Share (TTM)?

The Danaher EPS (TTM) is 5.03.

When Is the Next Danaher Earnings Date?

Danaher will release its next earnings report on Apr 28, 2026.

From a Technical Analysis Perspective, Is DHR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Danaher Stock Split?

Danaher has split 5 times.

How Many Employees Does Danaher Have?

Danaher has 60000 employees.

What is the current trading status of Danaher (DHR)?

As of Feb 06, 2026, Danaher (DHR) is trading at a price of 215.75, with a previous close of 215.75. The stock has fluctuated within a day range of 214.94 to 220.00, while its 52-week range spans from 171.00 to 242.80.

What Is Danaher (DHR) Price Target According to Analysts?

The average 12-month price target for Danaher is USD264.86, with a high estimate of USD310 and a low estimate of USD220. 22 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +22.76% Upside potential.

What Is the DHR Premarket Price?

DHR's last pre-market stock price is 217.17. The pre-market share volume is 350.00, and the stock has decreased by 1.42, or 0.66%.

What Is the DHR After Hours Price?

DHR's last after hours stock price is 217.16, the stock has decreased by 1.41, or 0.65%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.